By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AbbVie 

1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


SEARCH JOBS

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company. AbbVie’s mission is to apply the expertise, dedication, and creativity of its people to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products — Imbruvica®, Venclexta™, and Empliciti™ — and a pipeline containing multiple promising new molecules that are being studied in nearly 200 clinical trials in 19 different types of cancer.

AbbVie is expanding its oncology hub on the West Coast, with three sites in the San Francisco Bay Area (Redwood City, South San Francisco, and Sunnyvale) focused on the discovery and development of novel oncology therapies. More than 1,000 AbbVie scientists, clinicians, and product developers with strong entrepreneurial roots work across these three sites. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments.

YEAR FOUNDED:

2013

LEADERSHIP:

CEO: Richard A. Gonzalez

CFO: William J. Chase

JOBS:

Please click here for Abbvie job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information..

FOLLOW ABBVIE:





Key Statistics


Email:
Ownership: Public

Web Site: AbbVie
Employees:
Symbol: ABBV
 



Industry
Pharmaceutical






Company News
AbbVie (ABBV) And Eisai Company (ESALY.PK) Obtain Additional Approval For New Indication Of Fully Human Anti-TNF-Alpha Monoclonal Antibody HUMIRA In The Treatment Of Non-Infectious Uveitis 9/28/2016 9:34:34 AM
AbbVie (ABBV) Showcases Commitment To Research And Innovation In Dermatology At The 25th European Academy Of Dermatology And Venereology Congress 9/26/2016 10:07:13 AM
AbbVie (ABBV) Announces Submission Of A Supplemental New Drug Application For Ibrutinib (IMBRUVICA) For Treatment Of Marginal Zone Lymphoma 9/26/2016 7:26:59 AM
FDA Clears Amgen (AMGN) Copy of AbbVie (ABBV)'s Blockbuster Humira 9/26/2016 5:49:14 AM
Enanta Pharmaceuticals, Inc. Announces Data On Eight-Week Treatment Of AbbVie (ABBV)’s VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C 9/23/2016 9:31:01 AM
AbbVie (ABBV) Presents Data On Eight-Week Treatment Of VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C 9/23/2016 6:54:34 AM
BioArctic Enters Into Collaboration With AbbVie (ABBV) For Parkinson’s Disease Research 9/20/2016 10:57:24 AM
Karolinska Development AB Portfolio Company Bioarctic Enters Into Collaboration With AbbVie (ABBV) For Parkinson’s Disease Research 9/20/2016 9:33:17 AM
AbbVie (ABBV) And Biogen (BIIB) Release: New Data Presented At ECTRIMS Reinforce Efficacy Of ZINBRYTA (Daclizumab) And Support Long-Term Safety Profile 9/15/2016 11:15:16 AM
AbbVie (ABBV) Launches 2016 Thriving Student Scholarship Contest To Award Two Inspirational Students With Cystic Fibrosis $24,000 Each In Educational Funds 9/13/2016 12:00:57 PM
12345678910...
//-->